AIMS/HYPOTHESIS: The optimal HbA(1c) concentration for prevention of macrovascular complications and deaths in obese cardiovascular high-risk patients with type 2 diabetes remains to be established and was therefore studied in this post hoc analysis of the Sibutramine Cardiovascular OUTcomes (SCOUT) trial, which enrolled overweight and obese patients with type 2 diabetes and/or cardiovascular disease. METHODS: HRs for meeting the primary endpoint (nonfatal myocardial infarction, nonfatal stroke, resuscitated cardiac arrest or cardiovascular death) and all-cause mortality were analysed using Cox regression models. RESULTS: Of 8,252 patients with type 2 diabetes included in SCOUT, 7,479 had measurements of HbA(1c) available at baseline (i.e. study randomisation). Median age was 62 years (range 51-86 years), median BMI was 34.0 kg/m(2) (24.8-65.1 kg/m(2)) and 44% were women. The median HbA(1c) concentration was 7.2% (3.8-15.9%) (55 mmol/l [18-150 mmol/l]) and median diabetes duration was 7 years (0-57 years). For each 1 percentage point HbA(1c) increase, the adjusted HR for the primary endpoint was 1.17 (95% CI 1.11, 1.23); no differential sex effect was observed (p = 0.12 for interaction). In contrast, the risk of all-cause mortality was found to be greater in women than in men: HR 1.22 (1.10, 1.34) vs 1.12 (1.04, 1.20) for each 1 percentage point HbA(1c) increase (p = 0.02 for interaction). There was no evidence of increased risk associated with HbA(1c) ≤ 6.4% (≤ 46 mmol/l). Glucose-lowering treatment regimens, diabetes duration or a history of cardiovascular disease did not modify the associations. CONCLUSIONS/ INTERPRETATION: In overweight, cardiovascular high-risk patients with type 2 diabetes, increasing HbA(1c) concentrations were associated with increasing risks of cardiovascular adverse outcomes and all-cause mortality.
RCT Entities:
AIMS/HYPOTHESIS: The optimal HbA(1c) concentration for prevention of macrovascular complications and deaths in obese cardiovascular high-risk patients with type 2 diabetes remains to be established and was therefore studied in this post hoc analysis of the Sibutramine Cardiovascular OUTcomes (SCOUT) trial, which enrolled overweight and obesepatients with type 2 diabetes and/or cardiovascular disease. METHODS: HRs for meeting the primary endpoint (nonfatal myocardial infarction, nonfatal stroke, resuscitated cardiac arrest or cardiovascular death) and all-cause mortality were analysed using Cox regression models. RESULTS: Of 8,252 patients with type 2 diabetes included in SCOUT, 7,479 had measurements of HbA(1c) available at baseline (i.e. study randomisation). Median age was 62 years (range 51-86 years), median BMI was 34.0 kg/m(2) (24.8-65.1 kg/m(2)) and 44% were women. The median HbA(1c) concentration was 7.2% (3.8-15.9%) (55 mmol/l [18-150 mmol/l]) and median diabetes duration was 7 years (0-57 years). For each 1 percentage point HbA(1c) increase, the adjusted HR for the primary endpoint was 1.17 (95% CI 1.11, 1.23); no differential sex effect was observed (p = 0.12 for interaction). In contrast, the risk of all-cause mortality was found to be greater in women than in men: HR 1.22 (1.10, 1.34) vs 1.12 (1.04, 1.20) for each 1 percentage point HbA(1c) increase (p = 0.02 for interaction). There was no evidence of increased risk associated with HbA(1c) ≤ 6.4% (≤ 46 mmol/l). Glucose-lowering treatment regimens, diabetes duration or a history of cardiovascular disease did not modify the associations. CONCLUSIONS/ INTERPRETATION: In overweight, cardiovascular high-risk patients with type 2 diabetes, increasing HbA(1c) concentrations were associated with increasing risks of cardiovascular adverse outcomes and all-cause mortality.
Authors: Elizabeth Selvin; Josef Coresh; Sherita H Golden; Frederick L Brancati; Aaron R Folsom; Michael W Steffes Journal: Arch Intern Med Date: 2005-09-12
Authors: W Philip T James; Ian D Caterson; Walmir Coutinho; Nick Finer; Luc F Van Gaal; Aldo P Maggioni; Christian Torp-Pedersen; Arya M Sharma; Gillian M Shepherd; Richard A Rode; Cheryl L Renz Journal: N Engl J Med Date: 2010-09-02 Impact factor: 91.245
Authors: Charlotte Andersson; Mette L Norgaard; Peter R Hansen; Emil L Fosbøl; Michelle Schmiegelow; Peter Weeke; Jonas B Olesen; Jakob Raunsø; Casper H Jørgensen; Allan Vaag; Lars Køber; Christian Torp-Pedersen; Gunnar H Gislason Journal: Eur J Heart Fail Date: 2010-09-23 Impact factor: 15.534
Authors: Elizabeth Selvin; Michael W Steffes; Hong Zhu; Kunihiro Matsushita; Lynne Wagenknecht; James Pankow; Josef Coresh; Frederick L Brancati Journal: N Engl J Med Date: 2010-03-04 Impact factor: 91.245
Authors: Edward Giovannucci; David M Harlan; Michael C Archer; Richard M Bergenstal; Susan M Gapstur; Laurel A Habel; Michael Pollak; Judith G Regensteiner; Douglas Yee Journal: CA Cancer J Clin Date: 2010-06-16 Impact factor: 508.702
Authors: Sheldon Greenfield; John Billimek; Fabio Pellegrini; Monica Franciosi; Giorgia De Berardis; Antonio Nicolucci; Sherrie H Kaplan Journal: Ann Intern Med Date: 2009-12-15 Impact factor: 25.391
Authors: Ida Gustafsson; Bente Brendorp; Marie Seibaek; Hans Burchardt; Per Hildebrandt; Lars Køber; Christian Torp-Pedersen Journal: J Am Coll Cardiol Date: 2004-03-03 Impact factor: 24.094
Authors: Weiqin Li; Peter T Katzmarzyk; Ronald Horswell; Yujie Wang; Jolene Johnson; Gang Hu Journal: Int J Cardiol Date: 2015-09-26 Impact factor: 4.164
Authors: S Goswami; S W Yee; F Xu; S B Sridhar; J D Mosley; A Takahashi; M Kubo; S Maeda; R L Davis; D M Roden; M M Hedderson; K M Giacomini; R M Savic Journal: Clin Pharmacol Ther Date: 2016-09-23 Impact factor: 6.875
Authors: Evangelos Kontopantelis; David A Springate; David Reeves; Darren M Ashcroft; Martin K Rutter; Martin Rutter; Iain Buchan; Tim Doran Journal: Diabetologia Date: 2014-12-16 Impact factor: 10.122
Authors: Luc Bruyndonckx; Vicky Y Hoymans; Amaryllis H Van Craenenbroeck; Dirk K Vissers; Christiaan J Vrints; José Ramet; Viviane M Conraads Journal: Oxid Med Cell Longev Date: 2013-04-03 Impact factor: 6.543